Orwin John A 4

What Happened

• John A. Orwin, a director of AnaptysBio, had 6,030 restricted stock units (RSUs) vest and convert into 6,030 shares of common stock on June 15, 2026. The filing shows an acquisition/conversion of a derivative instrument (code M) into 6,030 shares at $0.00 — i.e., no cash was paid on settlement. The filing also shows a corresponding derivative disposition line reflecting the conversion/settlement.

Key Details

• Transaction date: June 15, 2026 (filed June 17, 2026 — filed within the normal 2-business-day window)
• Reported transactions: 6,030 shares acquired via conversion of derivative (code M) at $0.00; matching 6,030-share derivative disposition also reported
• Consideration: RSUs settle for no cash consideration (footnote F1)
• Vesting: RSUs vested 100% on June 15, 2026, subject to continued service (footnote F2)
• Shares owned after transaction: Not specified in the provided filing
• Filing timeliness: Filing date is June 17 for a June 15 transaction (timely under Section 16 reporting)

Context

• These entries reflect RSU vesting and settlement (a non‑cash award conversion) rather than an open‑market purchase or sale. The simultaneous acquisition and disposition lines are typical when a derivative award (RSU) converts into common shares on settlement. Such awards are routine compensation and do not by themselves indicate the insider’s market view.